Austria: These 13 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: Austria Patent E457719

CREON is a drug marketed by

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Austria Patent E488227

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 21, 2026
Generic Entry Controlled by: Austria Patent E491455

RASUVO is a drug marketed by Medexus. There is one patent protecting this drug.

This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: Austria Patent E480532

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.

Generic name: famotidine; ibuprofen
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 18, 2026
Generic Entry Controlled by: Austria Patent E539747

DUEXIS is a drug marketed by Horizon. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries. There has been litigation on patents covering DUEXIS

See drug price trends for DUEXIS.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this API. Sixteen suppliers are listed for this generic product. Additional details are available on the famotidine; ibuprofen profile page.

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: Austria Patent E523486

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 11, 2027
Generic Entry Controlled by: Austria Patent E556386

QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

Generic name: isavuconazonium sulfate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 25, 2026
Generic Entry Controlled by: Austria Patent E459342

CRESEMBA is a drug marketed by Astellas. There are three patents protecting this drug.

This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA

See drug price trends for CRESEMBA.

The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.

Generic name: benzgalantamine gluconate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: Austria Patent E473219

ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.

Generic name: sofpironium bromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 13, 2026
Generic Entry Controlled by: Austria Patent E529399

SOFDRA is a drug marketed by Botanix Sb. There are twenty patents protecting this drug.

This drug has one hundred and sixty-five patent family members in twenty-six countries. There has been litigation on patents covering SOFDRA

The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sofpironium bromide profile page.

Generic name: sofpironium bromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 13, 2026
Generic Entry Controlled by: Austria Patent E529400

SOFDRA is a drug marketed by Botanix Sb. There are twenty patents protecting this drug.

This drug has one hundred and sixty-five patent family members in twenty-six countries. There has been litigation on patents covering SOFDRA

The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sofpironium bromide profile page.

Generic name: niraparib tosylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 10, 2027
Generic Entry Controlled by: Austria Patent E502933

ZEJULA is a drug marketed by Glaxosmithkline. There are eight patents protecting this drug.

This drug has two hundred and eighty-five patent family members in fifty-five countries. There has been litigation on patents covering ZEJULA

See drug price trends for ZEJULA.

The generic ingredient in ZEJULA is niraparib tosylate. One supplier is listed for this generic product. Additional details are available on the niraparib tosylate profile page.

Generic name: abiraterone acetate; niraparib tosylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 10, 2027
Generic Entry Controlled by: Austria Patent E502933

AKEEGA is a drug marketed by Janssen Biotech. There are thirteen patents protecting this drug.

This drug has three hundred and fourteen patent family members in fifty-seven countries. There has been litigation on patents covering AKEEGA

See drug price trends for AKEEGA.

The generic ingredient in AKEEGA is abiraterone acetate; niraparib tosylate. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the abiraterone acetate; niraparib tosylate profile page.

Generic name: cobimetinib fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 05, 2026
Generic Entry Controlled by: Austria Patent E504565

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

This drug has two hundred and seven patent family members in forty-six countries.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this generic product. Additional details are available on the cobimetinib fumarate profile page.